CYDY - Interpretation Of Cytodyn's Mild-To-Moderate Covid-19 Results
The Proposition
The proposition of Cytodyn (CYDY) is that its humanized monoclonal antibody molecule, leronlimab, which blocks the CCR5 receptor on T cells and macrophages can prevent cytokine and chemokine mischief including metastasis and in the present results, the cytokine storms in the lungs resulting in acute respiratory distress syndrome (ARDS) in Covid-19 patients which leads to ventilators, and many times, in death.
Cytodyn reported results on Tuesday morning, July 21, of a Covid-19 trial in which there were 28 control (or placebo) subjects, and 56 test subjects. Please find their